The digital transformation in the biopharmaceutical industry is undergoing a shift from "chat assistants" to "agentic AI." Recently, Bristol Myers Squibb (BMS) officially announced a strategic partnership with the artificial intelligence startup Anthropic, adopting Claude Enterprise as the company's unified intelligent platform for global operations, and opening access to this advanced AI system for more than 30,000 employees worldwide.

From "Conversation" to "Agent": Deep Applications of AI in Pharmaceutical R&D

This collaboration marks a significant evolution in BMS's AI deployment strategy. Instead of merely using basic conversational tools, BMS is now integrating Claude's agentic capabilities seamlessly into daily workflows and core systems. This deployment focuses on three key priority areas:

Accelerating Software and Algorithm Development: By leveraging Anthropic's programming tool Claude Code, BMS's engineering and data science teams can significantly speed up software development. This not only standardizes collaboration across business lines but also breaks down long-standing "data silos" in the biopharmaceutical industry, enabling the reconstruction and utilization of data and expert knowledge locked in various systems.

Embedding Intelligent Agents in Core Value Chains: BMS is evaluating the integration of Claude as an agentic layer into its high-frequency workflows:

Drug Discovery: Utilizing AI's advanced reasoning capabilities to process decades of scientific, molecular, and clinical data, assisting researchers in identifying and optimizing targets in fields such as oncology and hematology.

Clinical Development: From drafting clinical study reports to preparing patient safety narratives, AI will automatically handle tedious documentation tasks, aiming to significantly shorten the cycle from "data lock" to "filing."

Production and Quality Control: Achieving full automation from root cause investigations to corrective and preventive action (CAPA) documentation, optimizing batch release decisions, thereby speeding up production while ensuring compliance.

Activating Institutional Knowledge Bases: Through secure integration with internal scientific, clinical, and commercial databases, Claude can retrieve cross-departmental expertise in real time, ensuring that every employee has the most accurate contextual support when making decisions.

Industry Background: The "Efficiency Leap" from McKinsey's Perspective

McKinsey previously predicted that Agentic AI could significantly reshape the operational models of the biopharmaceutical industry in the next five years, with clinical R&D efficiency potentially increasing by about 35% to 45%. This prediction is gradually becoming a reality: AI can optimize clinical trial design, accelerate subject matching, and reduce attrition rates by deeply analyzing historical trial data, real-world evidence, and patient records, helping pharmaceutical companies gain a competitive edge in the drug development race.

Competing in the Life Sciences Race: The "Battle" Between Anthropic and OpenAI

This collaboration further solidifies Anthropic's position in the life sciences sector. In fact, competition in this space has become extremely intense: OpenAI has previously entered agreements with Moderna and Novo Nordisk, deeply participating in drug discovery and process automation. Faced with the pressure from giants and competitors, Anthropic is striving to embed its "intelligent layer" at the core of global pharmaceutical infrastructure, relying on Claude's reasoning capabilities and commitment to enterprise data security.

For Bristol Myers Squibb, this is not just a technological upgrade but a crucial step toward becoming an AI-driven pharmaceutical company. By transforming artificial intelligence from a mere auxiliary tool into an "intelligent agent" capable of performing tasks independently, BMS is attempting to address the industry's long-standing issues of lengthy development cycles and high costs, delivering innovative drugs to patients around the world faster.